Continuous Infusion Cisplatin and Etoposide Chemotherapy for Cancer of Unknown Primary Site (CUPS) in Taiwan, a Region with a High Prevalence of Endemic Viral Infections

J. M. Liu, Y. M. Chen, Y. Chao, S. M. Liu, C. M. Tiu, H. W. Wu, T. C. Chiou, R. K. Hsieh, L. T. Chen, J. Whang-Peng

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: To evaluate the efficacy and toxicity of cisplatin/etoposide continuous infusion chemotherapy for cancer of unknown primary site in Taiwan, a region with a high prevalence of endemic viral infections. Method: Between April 1994 and February 1996, 20 patients with a diagnosis of CUPS were treated, including 15 males and five females, of average age 63.3 years (range 41-83 years). Continuous intravenous infusion of etoposide 80 mg/m2 and cisplatin 25 mg/m2 was given for 3 days every 3 weeks. Pretreatment tumor marker and viral serology studies were performed for baseline evaluation. Nearly two-thirds of the patients had poorly differentiated carcinoma. The average number of metastatic sites was 2.65 (range 1-4), with liver and lymph node involvement predominating. Results: The overall response rate was 25% (95% Cl 17.7-32.3%); 30.7% for poorly differentiated cancers and 25% for well differentiated cancers. Median survival was 4 months (range 1-12 months), 4.8 months for patients attaining partial response. Toxicity was moderate, grade 3 and 4 neutropenia occurred in 55% and grade 3 and 4 thrombocytopenia in 40%; other toxicities were mild. CA125 and CA199 were elevated in more than 50% of patients. Viral serology studies were not significantly different from those of the indigenous population. Conclusion: Etoposide and cisplatin combination chemotherapy has modest activity in patients with extensive CUPS and, at the schedule and dosage given, it is associated with moderate toxicity.

Original languageEnglish
Pages (from-to)431-435
Number of pages5
JournalJapanese Journal of Clinical Oncology
Volume28
Issue number7
DOIs
Publication statusPublished - Jan 1 1998
Externally publishedYes

Fingerprint

Etoposide
Virus Diseases
Taiwan
Cisplatin
Drug Therapy
Serology
Neoplasms
Tumor Biomarkers
Combination Drug Therapy
Neutropenia
Population Groups
Intravenous Infusions
Appointments and Schedules
Lymph Nodes
Carcinoma
Survival
Liver

Keywords

  • Cancer of unknown primary site (CUPS)
  • Cisplatin
  • Etoposide
  • Tumor markers

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Continuous Infusion Cisplatin and Etoposide Chemotherapy for Cancer of Unknown Primary Site (CUPS) in Taiwan, a Region with a High Prevalence of Endemic Viral Infections. / Liu, J. M.; Chen, Y. M.; Chao, Y.; Liu, S. M.; Tiu, C. M.; Wu, H. W.; Chiou, T. C.; Hsieh, R. K.; Chen, L. T.; Whang-Peng, J.

In: Japanese Journal of Clinical Oncology, Vol. 28, No. 7, 01.01.1998, p. 431-435.

Research output: Contribution to journalArticle

Liu, J. M. ; Chen, Y. M. ; Chao, Y. ; Liu, S. M. ; Tiu, C. M. ; Wu, H. W. ; Chiou, T. C. ; Hsieh, R. K. ; Chen, L. T. ; Whang-Peng, J. / Continuous Infusion Cisplatin and Etoposide Chemotherapy for Cancer of Unknown Primary Site (CUPS) in Taiwan, a Region with a High Prevalence of Endemic Viral Infections. In: Japanese Journal of Clinical Oncology. 1998 ; Vol. 28, No. 7. pp. 431-435.
@article{b38721a21b5249bca33bd54b7c8c52f8,
title = "Continuous Infusion Cisplatin and Etoposide Chemotherapy for Cancer of Unknown Primary Site (CUPS) in Taiwan, a Region with a High Prevalence of Endemic Viral Infections",
abstract = "Background: To evaluate the efficacy and toxicity of cisplatin/etoposide continuous infusion chemotherapy for cancer of unknown primary site in Taiwan, a region with a high prevalence of endemic viral infections. Method: Between April 1994 and February 1996, 20 patients with a diagnosis of CUPS were treated, including 15 males and five females, of average age 63.3 years (range 41-83 years). Continuous intravenous infusion of etoposide 80 mg/m2 and cisplatin 25 mg/m2 was given for 3 days every 3 weeks. Pretreatment tumor marker and viral serology studies were performed for baseline evaluation. Nearly two-thirds of the patients had poorly differentiated carcinoma. The average number of metastatic sites was 2.65 (range 1-4), with liver and lymph node involvement predominating. Results: The overall response rate was 25{\%} (95{\%} Cl 17.7-32.3{\%}); 30.7{\%} for poorly differentiated cancers and 25{\%} for well differentiated cancers. Median survival was 4 months (range 1-12 months), 4.8 months for patients attaining partial response. Toxicity was moderate, grade 3 and 4 neutropenia occurred in 55{\%} and grade 3 and 4 thrombocytopenia in 40{\%}; other toxicities were mild. CA125 and CA199 were elevated in more than 50{\%} of patients. Viral serology studies were not significantly different from those of the indigenous population. Conclusion: Etoposide and cisplatin combination chemotherapy has modest activity in patients with extensive CUPS and, at the schedule and dosage given, it is associated with moderate toxicity.",
keywords = "Cancer of unknown primary site (CUPS), Cisplatin, Etoposide, Tumor markers",
author = "Liu, {J. M.} and Chen, {Y. M.} and Y. Chao and Liu, {S. M.} and Tiu, {C. M.} and Wu, {H. W.} and Chiou, {T. C.} and Hsieh, {R. K.} and Chen, {L. T.} and J. Whang-Peng",
year = "1998",
month = "1",
day = "1",
doi = "10.1093/jjco/28.7.431",
language = "English",
volume = "28",
pages = "431--435",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Continuous Infusion Cisplatin and Etoposide Chemotherapy for Cancer of Unknown Primary Site (CUPS) in Taiwan, a Region with a High Prevalence of Endemic Viral Infections

AU - Liu, J. M.

AU - Chen, Y. M.

AU - Chao, Y.

AU - Liu, S. M.

AU - Tiu, C. M.

AU - Wu, H. W.

AU - Chiou, T. C.

AU - Hsieh, R. K.

AU - Chen, L. T.

AU - Whang-Peng, J.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Background: To evaluate the efficacy and toxicity of cisplatin/etoposide continuous infusion chemotherapy for cancer of unknown primary site in Taiwan, a region with a high prevalence of endemic viral infections. Method: Between April 1994 and February 1996, 20 patients with a diagnosis of CUPS were treated, including 15 males and five females, of average age 63.3 years (range 41-83 years). Continuous intravenous infusion of etoposide 80 mg/m2 and cisplatin 25 mg/m2 was given for 3 days every 3 weeks. Pretreatment tumor marker and viral serology studies were performed for baseline evaluation. Nearly two-thirds of the patients had poorly differentiated carcinoma. The average number of metastatic sites was 2.65 (range 1-4), with liver and lymph node involvement predominating. Results: The overall response rate was 25% (95% Cl 17.7-32.3%); 30.7% for poorly differentiated cancers and 25% for well differentiated cancers. Median survival was 4 months (range 1-12 months), 4.8 months for patients attaining partial response. Toxicity was moderate, grade 3 and 4 neutropenia occurred in 55% and grade 3 and 4 thrombocytopenia in 40%; other toxicities were mild. CA125 and CA199 were elevated in more than 50% of patients. Viral serology studies were not significantly different from those of the indigenous population. Conclusion: Etoposide and cisplatin combination chemotherapy has modest activity in patients with extensive CUPS and, at the schedule and dosage given, it is associated with moderate toxicity.

AB - Background: To evaluate the efficacy and toxicity of cisplatin/etoposide continuous infusion chemotherapy for cancer of unknown primary site in Taiwan, a region with a high prevalence of endemic viral infections. Method: Between April 1994 and February 1996, 20 patients with a diagnosis of CUPS were treated, including 15 males and five females, of average age 63.3 years (range 41-83 years). Continuous intravenous infusion of etoposide 80 mg/m2 and cisplatin 25 mg/m2 was given for 3 days every 3 weeks. Pretreatment tumor marker and viral serology studies were performed for baseline evaluation. Nearly two-thirds of the patients had poorly differentiated carcinoma. The average number of metastatic sites was 2.65 (range 1-4), with liver and lymph node involvement predominating. Results: The overall response rate was 25% (95% Cl 17.7-32.3%); 30.7% for poorly differentiated cancers and 25% for well differentiated cancers. Median survival was 4 months (range 1-12 months), 4.8 months for patients attaining partial response. Toxicity was moderate, grade 3 and 4 neutropenia occurred in 55% and grade 3 and 4 thrombocytopenia in 40%; other toxicities were mild. CA125 and CA199 were elevated in more than 50% of patients. Viral serology studies were not significantly different from those of the indigenous population. Conclusion: Etoposide and cisplatin combination chemotherapy has modest activity in patients with extensive CUPS and, at the schedule and dosage given, it is associated with moderate toxicity.

KW - Cancer of unknown primary site (CUPS)

KW - Cisplatin

KW - Etoposide

KW - Tumor markers

UR - http://www.scopus.com/inward/record.url?scp=0032113962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032113962&partnerID=8YFLogxK

U2 - 10.1093/jjco/28.7.431

DO - 10.1093/jjco/28.7.431

M3 - Article

VL - 28

SP - 431

EP - 435

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 7

ER -